Sirolimus-eluting stents: opposite in vitro effects on the clonogenic cell potential on a long-term exposure
Metrics: PDF 236 views | Full Text 666 views | ?
Francesco Vasuri1, Alessio Degiovanni1, Mauro Gargiulo3, William G. Thilly2, Elena V. Gostjeva2, Gianandrea Pasquinelli1 and Silvia Fittipaldi1,2
1 Pathology Unit, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna University, Bologna, Italy
2 Laboratory in Metakaryotic Biology (LIMB), Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
3 Vascular Surgery Unit, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna University, Bologna, Italy
Keywords: atherosclerosis; cell proliferation; sirolimus; stents
Abbreviations: DES: drug-eluting stents; DMSO: dimethyl sulfoxide; mTOR: mammalian target of Rapamycin; SES: sirolimus-eluting stent
Received: February 11, 2020 Accepted: March 19, 2020 Published: August 04, 2020
We evaluated the long-term effects of sirolimus on three different cell in vitro models, cultured in physiological conditions mimicking sirolimus-eluted stent, in order to clarify the effectiveness of sirolimus in blocking cell proliferation and survival.
Three cells lines (WPMY-1 myofibroblasts, HT-29 colorectal adenocarcinoma, and U2OS osteosarcoma) were selected and growth in 10 ml of Minimum Essential Medium for 5 weeks with serial dilutions of sirolimus. The number of colonies and the number of cells per colony were counted.
As main result, the number of WPMY-1 surviving colonies increased in a dose-dependent manner when treated with sirolimus (p = 0.0011), while the number of U2OS colonies progressively decreased (p = 0.0011). The clonal capacity of HT-29 was not modified by the exposure to sirolimus (p = 0.6679).
In conclusion sirolimus showed the well-known cytostatic effect, but with an effect on clonogenic potential different among the different cell types. In the practice, the plaque typology and composition may influence the response to sirolimus and thus the effectiveness of eluted stent.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.